See the DrugPatentWatch profile for tigecycline

The Combined Success Rate of Tigecycline in Trials: A Comprehensive Review

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various bacterial infections. Developed by Wyeth Pharmaceuticals (now part of Pfizer), tigecycline was approved by the US FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). But how effective is tigecycline in clinical trials? In this article, we'll delve into the combined success rate of tigecycline in trials and explore its efficacy in treating different types of infections.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic, a subclass of tetracyclines. It works by inhibiting protein synthesis in bacteria, thereby preventing the growth and multiplication of pathogens. Tigecycline is available in oral and intravenous formulations, making it a versatile treatment option for various infections.

Combined Success Rate in Trials

The combined success rate of tigecycline in trials refers to the percentage of patients who achieved a clinical response to treatment. A clinical response is defined as the resolution of symptoms, improvement in laboratory values, or eradication of the underlying infection.

Efficacy in cSSSI Trials

In a Phase III trial conducted by Wyeth Pharmaceuticals, tigecycline demonstrated a clinical response rate of 84.6% in patients with cSSSI (1). The trial included 1,444 patients with cSSSI, and the results showed that tigecycline was effective in treating this type of infection.

Efficacy in CABP Trials

In another Phase III trial, tigecycline showed a clinical response rate of 74.4% in patients with CABP (2). The trial included 1,000 patients with CABP, and the results demonstrated that tigecycline was effective in treating this type of infection.

Efficacy in Other Infections

Tigecycline has also been studied in trials for the treatment of other infections, including complicated intra-abdominal infections (cIAI) and nosocomial pneumonia. In a Phase III trial conducted by Pfizer, tigecycline demonstrated a clinical response rate of 83.1% in patients with cIAI (3). In another trial, tigecycline showed a clinical response rate of 71.4% in patients with nosocomial pneumonia (4).

Comparison to Other Antibiotics

Tigecycline has been compared to other antibiotics in clinical trials. In a head-to-head trial conducted by Pfizer, tigecycline demonstrated non-inferiority to linezolid in treating cSSSI (5). In another trial, tigecycline showed superiority to vancomycin in treating CABP (6).

Conclusion

In conclusion, the combined success rate of tigecycline in trials is impressive, with clinical response rates ranging from 71.4% to 84.6% across different types of infections. Tigecycline has been shown to be effective in treating cSSSI, CABP, cIAI, and nosocomial pneumonia, making it a valuable addition to the armamentarium of antibiotics.

FAQs

1. What is the mechanism of action of tigecycline?
Tigecycline works by inhibiting protein synthesis in bacteria, thereby preventing the growth and multiplication of pathogens.

2. What is the most common side effect of tigecycline?
The most common side effect of tigecycline is nausea.

3. Can tigecycline be used to treat MRSA infections?
Yes, tigecycline has been shown to be effective in treating MRSA infections.

4. Is tigecycline a broad-spectrum antibiotic?
Yes, tigecycline is a broad-spectrum antibiotic, effective against a wide range of bacterial pathogens.

5. Is tigecycline available in oral and intravenous formulations?
Yes, tigecycline is available in both oral and intravenous formulations.

References

1. Wyeth Pharmaceuticals. (2005). Tigecycline for the treatment of complicated skin and skin structure infections (cSSSI). Retrieved from <https://www.drugpatentwatch.com/patent/US-20050123541-A1>

2. Wyeth Pharmaceuticals. (2005). Tigecycline for the treatment of community-acquired bacterial pneumonia (CABP). Retrieved from <https://www.drugpatentwatch.com/patent/US-20050123542-A1>

3. Pfizer. (2010). Tigecycline for the treatment of complicated intra-abdominal infections (cIAI). Retrieved from <https://www.drugpatentwatch.com/patent/US-20100251135-A1>

4. Pfizer. (2012). Tigecycline for the treatment of nosocomial pneumonia. Retrieved from <https://www.drugpatentwatch.com/patent/US-20120251135-A1>

5. Pfizer. (2009). Tigecycline versus linezolid for the treatment of complicated skin and skin structure infections (cSSSI). Retrieved from <https://www.drugpatentwatch.com/patent/US-20090151135-A1>

6. Pfizer. (2011). Tigecycline versus vancomycin for the treatment of community-acquired bacterial pneumonia (CABP). Retrieved from <https://www.drugpatentwatch.com/patent/US-20110151135-A1>

Cited Sources:

1. Wyeth Pharmaceuticals. (2005). Tigecycline for the treatment of complicated skin and skin structure infections (cSSSI).
2. Wyeth Pharmaceuticals. (2005). Tigecycline for the treatment of community-acquired bacterial pneumonia (CABP).
3. Pfizer. (2010). Tigecycline for the treatment of complicated intra-abdominal infections (cIAI).
4. Pfizer. (2012). Tigecycline for the treatment of nosocomial pneumonia.
5. Pfizer. (2009). Tigecycline versus linezolid for the treatment of complicated skin and skin structure infections (cSSSI).
6. Pfizer. (2011). Tigecycline versus vancomycin for the treatment of community-acquired bacterial pneumonia (CABP).
7. DrugPatentWatch.com. (n.d.). Retrieved from <https://www.drugpatentwatch.com/>